title: Modulation of proteolytic activity during neuritogenesis in the PC12 nerve cell: differential control of plasminogen activator and plasminogen activator inhibitor activities by nerve growth factor and dibutyryl-cyclic AMP.
abstract: Extracellular proteolysis is considered to be required during neuritic outgrowth to control the adhesiveness between the growing neurite membrane and extracellular matrix proteins. In this work, PC12 nerve cells were used to study the modulation of proteolytic activity during neuronal differentiation. PC12 cells were found to contain and release a 70-75-kDa tissue-type plasminogen activator (tPA) and a much less abundant 48-kDa urokinase-type plasminogen activator. A plasminogen activator inhibitor (PAI) activity with molecular sizes of 54 and 58 kDa was also detected in PC12 cell conditioned medium and formed high-molecular-mass complexes with released tPA. Release of PAI activity was dependent on treatment with nerve growth factor (NGF), whereas tPA synthesis and release were under control of a cyclic AMP-dependent mechanism and increased on treatment with dibutyryl-cyclic AMP [(But)2cAMP] or cholera toxin. Simultaneous treatment with NGF and (But)2cAMP resulted in increases of both tPA and PAI release and enhancement of tPA-PAI complex formation. The resulting plasminogen activator activity in conditioned medium was high in (But)2cAMP-treated cultures with short neuritic outgrowth but remained low in NGF- or NGF plus (But)2cAMP-treated cultures, where neurite extension was, respectively, large and very large. These results suggest that excess proteolytic activity may be detrimental to neuritic outgrowth and that not only PAI release but also tPA-PAI complex formation is associated with production of large and stable neuritic outgrowth. This can be understood as an involvement of PAI in the protection against neurite-destabilizing proteolytic activity.
authors.affiliation: Department of Human Physiology, Université de Liège, Belgium.
authors.forename: P
authors.initials: P
authors.lastname: Leprince
authors.forename: B
authors.initials: B
authors.lastname: Rogister
authors.forename: P
authors.initials: P
authors.lastname: Delrée
authors.forename: J M
authors.initials: JM
authors.lastname: Rigo
authors.forename: B
authors.initials: B
authors.lastname: André
authors.forename: G
authors.initials: G
authors.lastname: Moonen
mesh_terms: D000310:Adrenal Gland Neoplasms; D000818:Animals; D001369:Axons / Q000502:physiology*; D003994:Bucladesine / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D000242:Cyclic AMP / Q000502:physiology; D007700:Kinetics; D009414:Nerve Growth Factors / Q000494:pharmacology*; D010673:Pheochromocytoma; D010960:Plasminogen Activators / Q000302:isolation & purification / Q000378:metabolism*; D015849:Plasminogen Inactivators / Q000378:metabolism*; D051381:Rats
chemical_list: D009414:Nerve Growth Factors; D015849:Plasminogen Inactivators; D003994:Bucladesine; D000242:Cyclic AMP; D010960:Plasminogen Activators